DJS Law Group said investors who bought Capricor Therapeutics shares during the class period from December 17, 2025 to July 26, 2026 have until September 28, 2026 to seek appointment as lead plaintiff in a securities class action. The complaint alleges Capricor violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC (U.S. securities regulator) Rule 10b-5 by making false and misleading statements to the market. The filing centers on allegations that Capricor changed the statistical analysis plan used for Deramiocel clinical data, did not secure the FDA's agreement to that change before resubmitting a Biologics License Application (formal request to market a biologic drug), and therefore misled investors throughout the class period. DJS Law Group said lead plaintiff status is not required for shareholders to participate in any recovery.